News

InSysBio has presented a new portion of results in the framework of development of COVID-19 QSP model.

InSysBio continues to move forward in COVID-19 QSP model development. Its aim is to describe virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.

InSysBio continues to investigate the mechanisms underlying Alzheimer’s disease (AD) using the quantitative systems pharmacology (QSP) modeling approach. The part of QSP model describing tau protein was published in the PLOS ONE journal. This is one of more than dozen InSysBio publications in AD area during last seven years.

Moscow, Russia, July 14, 2017. The scientists from BIND RUS and InSysBio (www.insysbio.ru) published a joint research of the new class of anti-oncology treatment in the Journal of Controlled Release. Unique nanoparticles enriched with medications can deliver its content targeted to the tumor site, and the parameters of their effectiveness are programmed during the forming phase.

Moscow, Russia - 21 June, 2017. InSysBio scientific group led by Tatiana Karelina developed a quantitative system pharmacology model of Alzheimer’s disease. First part published in CPT PSP shows how to design initial phases of clinical trials of new drugs and to interpret the data obtained.

Moscow, Russia - November 29th, 2016. Institute for Systems Biology Moscow (www.insysbio.ru), one of the pioneers in bio-modeling and simulation announced the study made in collaboration with scientists of two pharmaceutical leaders: MedImmune and AstraZeneca.